FDA Approves First Gene Therapy to Treat Inherited Hearing Loss Caused by OTOF Mutations

The U.S. Food and Drug Administration has granted accelerated approval to the first-ever gene therapy designed to treat a genetic form of hearing loss. The one-time treatment, developed by Regeneron Pharmaceuticals and marketed as Otarmeni (lunsotogene parvec-cwha), restores functional hearing in patients born with severe-to-profound deafness caused by mutations in the OTOF gene.

This landmark regulatory decision fundamentally alters the landscape of auditory medicine. Historically, congenital deafness has been managed with prosthetic devices like hearing aids or cochlear implants. While these devices amplify sound or bypass damaged structures to stimulate the auditory nerve, they do not restore the full, natural spectrum of human hearing.[2][4]

Otarmeni represents a shift from mechanical management to biological restoration. By delivering a functional copy of the defective gene directly into the inner ear, the therapy allows the body to rebuild its own sensory transmission infrastructure. For the families of children born into a silent world, the intervention offers the unprecedented possibility of 24/7 natural hearing.[1][3]

The specific condition targeted by Otarmeni is an ultra-rare genetic disorder known as OTOF-related hearing loss. In the United States, this condition affects approximately 50 newborns each year.[3]

In patients with this mutation, all the major structural components of the ear—including the eardrum, the delicate bones of the middle ear, and the spiral-shaped cochlea—are fully intact and physically capable of receiving sound waves.[4]

The breakdown occurs at the microscopic level. The OTOF gene is responsible for producing otoferlin, a critical protein that acts as a chemical messenger. Otoferlin enables the inner ear's sensory hair cells to communicate with the auditory nerve. Without it, the ear detects sound vibrations, but the brain never receives the signal.[3]

Otarmeni bridges this gap using a dual adeno-associated virus (AAV) vector system. Because the OTOF gene is unusually large, it cannot fit inside a single standard viral vector. Regeneron engineered a two-part delivery mechanism that transports the genetic payload in halves.[2][4]

During a specialized surgical procedure performed under general anesthesia, the viral vectors are infused directly into the patient's cochlea. Once inside the targeted inner hair cells, the two halves recombine to form a complete, functional OTOF gene, which immediately begins instructing the cells to manufacture otoferlin.[3]

The clinical evidence supporting the FDA's accelerated approval emerged from the pivotal Phase 1/2 CHORD trial, which enrolled infants, children, and adolescents. The results demonstrated rapid and profound biological efficacy.[2]

According to the trial data, 80% of evaluable participants achieved a significant improvement in hearing sensitivity by week 24, meeting the trial's primary endpoint of reaching an average threshold of 70 decibels or better.[2]

Even more striking were the longer-term outcomes. With extended follow-up, 42% of the evaluable participants achieved normal hearing thresholds. Researchers noted that these children were able to perceive sounds as quiet as a whisper, indicating a level of functional restoration far beyond basic threshold gains.[1][2]

The speed of the FDA's regulatory review was nearly as unprecedented as the science itself. Otarmeni was approved just 61 days after Regeneron submitted its Biologics License Application (BLA).

This rapid turnaround was facilitated by the FDA Commissioner's National Priority Voucher (CNPV) pilot program. Otarmeni is the first gene therapy, and only the second new molecular entity, to be approved under this specific pathway, which is designed to accelerate the development of treatments for rare diseases with high unmet medical needs.[1]

While the scientific achievement is monumental, the commercial strategy accompanying the launch has also drawn significant attention. Regeneron announced that it will provide Otarmeni entirely free of charge to eligible patients in the United States.[2]

However, the company noted that while the drug itself will be free, families and their insurance providers may still be responsible for the out-of-pocket costs associated with the surgical infusion, anesthesia, and subsequent hospital care.[2][3]

To be eligible for the therapy, patients must meet strict clinical criteria. They must have molecularly confirmed biallelic variants in the OTOF gene, their outer hair cell function must be preserved, and they cannot have a prior cochlear implant in the ear designated for treatment.[2]

Because Otarmeni received accelerated approval based on surrogate endpoints—specifically, the rapid improvement in hearing sensitivity—Regeneron is required to provide further confirmatory data. Continued FDA approval will hinge on the ongoing CHORD trial demonstrating durable, long-term clinical benefits, including sustained speech development and quality-of-life improvements.[3]

The success of Otarmeni is expected to catalyze further investment in auditory genetic medicine. Other pharmaceutical companies, including Eli Lilly's Akouos subsidiary, are currently advancing their own OTOF-targeted gene therapies through clinical trials, signaling the emergence of a robust new therapeutic category.[4]

Beyond otoferlin mutations, the validation of the dual AAV vector delivery system opens the door for treating other genetic forms of deafness. Researchers are already exploring how similar viral platforms could be used to deliver different genes to the inner ear, potentially addressing a much wider spectrum of congenital hearing disorders in the coming decade.[2][4]